EGFR and non-small cell lung carcinoma: Point mutations in exons 18, 19, and 21 represent 85% of EGFR mutation-positive NSCLC cases and have been shown to be responsive to targeted treatment using EGFR-specific tyrosine kinase inhibitors (TKIs) [8,9].